Lymphocyte-to-monocyte ratio predicts survival of patients with hepatocellular carcinoma after curative resection

Table 3 Cox proportional hazards model of prognostic factors for recurrence-free survival in 210 patients with hepatocellular carcinoma after curative hepatectomy

Variable	Univariate analysis		Multivariate analysis
	HR (95%CI)	P value	HR (95%CI)	P value
Age(yr), ≥ 60 vs < 60	1.319 (0.859-2.027)	0.206
Gender, male vs female	0.855 (0.458-1.594)	0.621
Liver cirrhosis: yes vs no	1.316 (0.831-2.086)	0.242
ALT (U/L), > 75 vs ≤ 75	1.709 (1.096-2.665)	0.018	1.510 (0.960-2.375)	0.074
Total bilirubin (μmol/L), > 34 vs ≤ 34	1.471 (0.715-3.023)	0.294
Albumin (g/L), ≥ 35 vs < 35	0.279 (0.160-0.485)	< 0.001
ALP (U/L), > 100 vs ≤ 100	1.506 (0.964-2.354)	0.072
AFP (ng/dL), > 400 vs ≤ 400	0.934 (0.636-1.373)	0.730
Tumor size (cm), > 5 vs ≤ 5	2.020 (1.354-3.012)	0.001
Tumor number, multiple vs single	1.599 (0.953-2.684)	0.075
Portal vein thrombus, yes vs no	2.282 (1.150-4.529)	0.018
Microvascular invasion, yes vs no	1.185 (0.742-1.892)	0.478
Histological differentiation, poor vs well and moderate	2.628 (1.561-4.425)	< 0.001	2.610 (1.542-4.416)	< 0.001
BCLC stage, B + C vs 0 + A	1.724 (1.180-2.520)	0.005	1.645 (1.124-2.409)	0.010
Preoperative LMR, > 3.23 vs ≤ 3.23	0.601 (0.410-0.883)	0.009	0.584 (0.398-0.859)	0.006

AFP: Alpha-fetoprotein; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; BCLC: Barcelona Clinic Liver Cancer; LMR: Lymphocyte-to-monocyte ratio.